Notice: This company has been marked as potentially delisted and may not be actively trading. Lumos Pharma (LUMO) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Lumos Pharma (NASDAQ:LUMO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage25.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$12,572.01 Get LUMO Insider Trade Alerts Want to know when executives and insiders are buying or selling Lumos Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LUMO Insider Buying and Selling by Quarter Lumos Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/6/2024John C MckewInsiderSell3,407$1.89$6,439.23 4/3/2024John C MckewInsiderSell2,214$2.77$6,132.78 (Data available from 1/1/2013 forward) LUMO Insider Trading Activity - Frequently Asked Questions Who is on Lumos Pharma's Insider Roster? The list of insiders at Lumos Pharma includes John C Mckew, Richard J Hawkins, and Thomas A Raffin. Learn more on insiders at LUMO. What percentage of Lumos Pharma stock is owned by insiders? 25.40% of Lumos Pharma stock is owned by insiders. Learn more on LUMO's insider holdings. Which Lumos Pharma insiders have been selling company stock? The following insider sold LUMO shares in the last 24 months: John C Mckew ($32,075.40). How much insider selling is happening at Lumos Pharma? Insiders have sold a total of 11,680 Lumos Pharma shares in the last 24 months for a total of $32,075.40 sold. Lumos Pharma Key ExecutivesMr. Richard J. Hawkins (Age 75)Founder, CEO & Chairman Compensation: $854.35kDr. John C. McKew Ph.D. (Age 60)Chief Scientific Officer & President Compensation: $860.38kMs. Lori D. Lawley CPA (Age 40)CFO & Principal Accounting Officer Compensation: $538.23kMs. Lisa Wells MillerSenior Director of Investor RelationsMr. Bradley J. Powers J.D. (Age 45)Chief Compliance Officer & General Counsel Compensation: $677.08kMr. Aaron Schuchart B.B.A. (Age 58)CPA, M.B.A., Chief Business Officer Dr. Pisit Pitukcheewanont FAAPM.D., Chief Medical OfficerMr. Eddie L. Varnado M.B.A.Corporate Controller More Insider Trading Tools from MarketBeat Related Companies LXEO Insider Ownership ADAP Insider Ownership STRO Insider Ownership MCRB Insider Ownership PBYI Insider Ownership CHRS Insider Ownership BMEA Insider Ownership BDTX Insider Ownership CABA Insider Ownership TSVT Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:LUMO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
